Skip to content
UKKW 2026 Feedback Survey
*
1.
How would you rate the overall quality and content of the programme?
(1 = Poor, 5 = Excellent)
(Required.)
1
2
3
4
5
1
2
3
4
5
*
2.
Were there any sessions or speakers that particularly stood out to you? If so, why?
(Required.)
*
3.
Were there any sessions or speakers you felt were less effective or not a good use of your time? Please explain.
(Required.)
*
4.
Were there any key topics you felt were missing from this year’s programme? What would you like to see included next year?
(Required.)
*
5.
Did you submit a session proposal for UKKW 2026?
(Required.)
Yes
No
Comments
*
6.
Did you submit an abstract this year?
(Required.)
Yes
No
Comments
*
7.
Did you find it easy to navigate the electronic poster boards?
(Required.)
Yes
No
I didn't use the poster boards
Comments
*
8.
If you had an accepted poster presentation, how did you find the design and upload process?
(Required.)
Easy
I would have benefitted from a little more help and guidance
Difficult
I didn't present a poster (n/a)
Comments
*
9.
Please rate any sponsored sessions you attended from 1 - 5 (1 = Poor, 5 = Excellent)
(Required.)
1
2
3
4
5
N/A
GLP-1 RAs in Type 2 Diabetes and Chronic Kidney Disease: Clinical and Mechanistic
Insights from Recent Trials (Novo Nordisk, Tuesday)
1
2
3
4
5
N/A
Additional feedback
Rethinking IgA Nephropathy: Early Disease-Modifying Therapy and the Priority of
eGFR Stabilisation (STADA UK, Tuesday)
1
2
3
4
5
N/A
Additional feedback
B cell to Better Care: Translating Pathways into Patient Outcomes (Otsuka, Wednesday)
1
2
3
4
5
N/A
Additional feedback
Innovations in Cardio-Renal-Metabolic Disease: Addressing the Cardiorenal Consequences of Persistent RAAS
Dysregulation. A non-promotional LEMS discussion organised (Boehringer Ingelheim, Wednesday)
1
2
3
4
5
N/A
Additional feedback
Confronting the elephant in the room: Addressing the barriers to guideline directed CKD therapy (AstraZeneca, Wednesday)
1
2
3
4
5
N/A
Additional feedback
In Flames: Residual Inflammation, CKD and ASCVD (Novo Nordisk, Thursday)
1
2
3
4
5
N/A
Additional feedback
Personalising Anaemia Therapy (Medice UK, Thursday)
1
2
3
4
5
N/A
Additional feedback
The Unmet Need and Challenges of C3G and Primary IC-MPGN (Swedish Orphan Biovitrum Ltd)
1
2
3
4
5
N/A
Additional feedback
*
10.
Were there any exhibitors who stood out to you? If so, why?
(Required.)
*
11.
Were there any exhibitors, who were not at UK Kidney Week you would like to see included in future events?
(Required.)
*
12.
Did you feel there were sufficient networking opportunities during UK Kidney Week?
(Required.)
Yes
No
Comments
*
13.
Did you attend any of the social activities?
(Required.)
Yes
No
Comments
*
14.
How easy was it to find your way around the venue using the conference signage, map and directions? (1 = Poor, 5 = Excellent)
(Required.)
1
2
3
4
5
1
2
3
4
5
Comments
*
15.
How would you rate the overall visual identity and branding of the conference (e.g. signage design, displays, digital screens)? (1 = Poor, 5 = Excellent)
(Required.)
1
2
3
4
5
1
2
3
4
5
Comments
*
16.
How would you rate the conference app? (1 = Poor, 5 = Excellent)
(Required.)
1
2
3
4
5
1
2
3
4
5
Comments
*
17.
How did you travel to UK Kidney Week?
(Required.)
Train
Car
Lift Share
Plane
Bus
Bike
Walk
Other (please specify)
*
18.
Would you be interested in being a session chair in 2027?
(By selecting “Yes,” you agree to be contacted)
(Required.)
Yes
No
*
19.
Would you be interested in being a poster moderator in 2027?
(By selecting “Yes,” you agree to be contacted)
(Required.)
Yes
No
*
20.
Do you feel that UK Kidney Week represents good value for money?
(Required.)
Yes
No
Comments
*
21.
Do you plan to attend UK Kidney Week 2027 in Newport?
(Required.)
Yes
No
If no, please explain why?
*
22.
Do you require an attendance certificate?
(Required.)
Yes
No
23.
Name (as it should appear on attendance certificate)
24.
Email address
